Mark Schneyer Sells 10,262 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark Schneyer sold 10,262 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total value of $243,106.78. Following the sale, the executive vice president owned 53,338 shares of the company’s stock, valued at approximately $1,263,577.22. This represents a 16.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ACADIA Pharmaceuticals Price Performance

NASDAQ:ACAD traded down $0.70 during mid-day trading on Wednesday, reaching $23.10. The stock had a trading volume of 1,449,537 shares, compared to its average volume of 2,140,009. The stock has a market cap of $3.91 billion, a P/E ratio of 17.37, a PEG ratio of 7.90 and a beta of 0.80. The business’s 50 day moving average is $22.37 and its 200 day moving average is $22.44. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $13.40 and a fifty-two week high of $26.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.14 by $0.28. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The company had revenue of $278.63 million during the quarter, compared to the consensus estimate of $276.52 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ACAD. Cowen reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, September 11th. Deutsche Bank Aktiengesellschaft set a $29.00 price target on ACADIA Pharmaceuticals in a research note on Thursday, September 25th. JMP Securities boosted their target price on ACADIA Pharmaceuticals from $37.00 to $38.00 and gave the stock a “market outperform” rating in a report on Thursday, August 7th. Royal Bank Of Canada decreased their target price on ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating for the company in a research report on Thursday, November 6th. Finally, UBS Group lifted their price target on shares of ACADIA Pharmaceuticals from $36.00 to $39.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $28.83.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Maryland State Retirement & Pension System raised its position in ACADIA Pharmaceuticals by 1.3% in the 2nd quarter. Maryland State Retirement & Pension System now owns 36,397 shares of the biopharmaceutical company’s stock valued at $785,000 after purchasing an additional 476 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 11.2% during the third quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 534 shares during the last quarter. Vise Technologies Inc. increased its stake in shares of ACADIA Pharmaceuticals by 4.0% in the third quarter. Vise Technologies Inc. now owns 15,367 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 585 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of ACADIA Pharmaceuticals by 0.7% in the second quarter. Thrivent Financial for Lutherans now owns 91,067 shares of the biopharmaceutical company’s stock valued at $1,964,000 after buying an additional 626 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of ACADIA Pharmaceuticals by 25.8% in the third quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 690 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.